Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Blood (2015) 126 (23): 4240.

https://doi.org/10.1182/blood.V126.23.4240.4240

Published: 2015

Journal Articles

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

Blood (2015) 125 (18): 2771–2778.

https://doi.org/10.1182/blood-2014-09-601674

Published: 2015

Journal Articles

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Blood (2014) 124 (21): 3458.

https://doi.org/10.1182/blood.V124.21.3458.3458

Published: 2014

Journal Articles

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

Xiaojun Huang, Jianxiang Wang, MD, Michele Baccarani, MD, Svetlana Jevtic, Christine-Elke Ortmann, Ye Yuan, Hans D. Menssen, MD, PhD, Giuseppe Saglio, Zhi-Xiang Shen, MD

Blood (2013) 122 (21): 1497.

https://doi.org/10.1182/blood.V122.21.1497.1497

Published: 2013

Journal Articles

Bortezomib-Based Induction Therapy Followed by High-Dose Chemotherapy and Autologous Stem Cell transplantation in Newly-Diagnosed Myeloma: Initial Report From a Chinese Multiple-Center Study

Jiong Hu, Zhi-Xiang Shen

Blood (2012) 120 (21): 4557.

https://doi.org/10.1182/blood.V120.21.4557.4557

Published: 2012

Journal Articles

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Anna G Turkina, Zhi-Xiang Shen, H. Jean Khoury, Tim H Brümmendorf, Philippe Schafhausen, Edo Vellenga, Ricardo Pasquini, Vikram Mathews, Tamas Masszi, Simon Durrant, Kimmo Porkka, MD, PhD, Eric Leip, Virginia Kelly, Nadine Besson, Carlo Gambacorti-Passerini

Blood (2012) 120 (21): 3779.

https://doi.org/10.1182/blood.V120.21.3779.3779

Published: 2012

Journal Articles

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Jong Wook Lee, MD, PhD, Sung-Soo Yoon, MD, PhD, Zhi Xiang Shen, MD, Arnold Ganser, MD, Hui-Chi Hsu, MD, Ali El-Ali, MD, Dany Habr, MD, Bernard Roubert, PhD, John B. Porter, MD, on behalf of the EPIC study investigators

Blood (2011) 118 (21): 1344.

https://doi.org/10.1182/blood.V118.21.1344.1344

Published: 2011

Journal Articles

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Jorge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Dong-Wook Kim, Anna G. Turkina, Zhi-Xiang Shen, Ricardo Pasquini, H. Jean Khoury, Steven Arkin, Angela Volkert, Nadine Besson, Richat Abbas, Junyuan Wang, Eric Leip, Carlo Gambacorti-Passerini

Blood (2011) 118 (17): 4567–4576.

https://doi.org/10.1182/blood-2011-05-355594

Published: 2011

Includes: Supplemental data

Journal Articles

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Arnold Ganser, Hui-Chi Hsu, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter, on behalf of the EPIC study investigators

Blood (2010) 116 (14): 2448–2454.

https://doi.org/10.1182/blood-2010-01-261289

Published: 2010

Journal Articles

Long-Term Outcome of Imatinib Treatment in Chronic Myeloid Leukemia (CML) Patients in Shanghai: An International Patient Assistance Programs (GIPAP) Analysis.

Ai-hua Wang, Li Zhou, Yu Zheng, Jun-min Li, Zhi-Xiang Shen, MD, Jiong Hu, MD

Blood (2009) 114 (22): 4275.

https://doi.org/10.1182/blood.V114.22.4275.4275

Published: 2009

Journal Articles

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 4718.

https://doi.org/10.1182/blood.V114.22.4718.4718

Published: 2009

Journal Articles

A Multicentre, Randomized Study of FLAG Treatment in China(CHORT).

Hua Yan, Zhi-Xiang Shen, MD, Jianxiang Wang

Blood (2008) 112 (11): 948.

https://doi.org/10.1182/blood.V112.11.948.948

Published: 2008

Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

Jorge Cortes, MD, Hagop M Kantarjian, Dong- Wook Kim, MD, PhD, H. Jean Khoury, MD, FACP, Anna G. Turkina, MD, Zhi-Xiang Shen, MD, Tim H Brummendorf, MD, Mammen Chandy, MD, Steven Arkin, MD, Carlo Gambacorti-Passerini, MD

Blood (2008) 112 (11): 1098.

https://doi.org/10.1182/blood.V112.11.1098.1098

Published: 2008

Journal Articles

A Retrospective Study of Introferon-Alpha Treatment on Chinese Patients with Chronic Myeloid Leukemia

Hua Yan, Zhi-Xiang Shen, MD

Blood (2008) 112 (11): 4287.

https://doi.org/10.1182/blood.V112.11.4287.4287

Published: 2008

Journal Articles

Front-Line Therapy with Arsenic Trioxide/All- Trans -Retinoic Acid Combination and Chemotherapy Improves Cure Rates in Newly Diagnosed Patients with Acute Promyelocytic Leukemia

Jiong Hu, MD, Yuan-fang Liu, Chuan-feng Wu, Guang-biao Zhou, Zhi-Xiang Shen, Jun-min Li, Zhen-Yi Wang, Sai-Juan Chen, Zhu Chen

Blood (2008) 112 (11): 2970.

https://doi.org/10.1182/blood.V112.11.2970.2970

Published: 2008

Journal Articles

Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial

Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Hui-Chi Hsu, Arnold Ganser, Dany Habr, Gabor Domokos, Abdel Hmissi, John B Porter

Blood (2008) 112 (11): 439.

https://doi.org/10.1182/blood.V112.11.439.439

Published: 2008

Journal Articles

Bortezomib (Velcade ™ ) Observational Study in China: Efficacy and Safety of Bortezomib-Based Regimen in 395 Relapsed or Refractory Multiple Myeloma Patients

Zhi-Xiang Shen, Hua Yan, Linna Wang

Blood (2008) 112 (11): 5179.

https://doi.org/10.1182/blood.V112.11.5179.5179

Published: 2008

Journal Articles

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor

Wei-Li Zhao, Yan-Yan Liu, Qun-Ling Zhang, Li Wang, Christophe Leboeuf, Yi-Wen Zhang, Jie Ma, José-Francisco Garcia, Yong-Ping Song, Jun-Min Li, Zhi-Xiang Shen, Zhu Chen, Anne Janin, Sai-Juan Chen

Blood (2008) 111 (7): 3867–3871.

https://doi.org/10.1182/blood-2007-08-108654

Published: 2008

Journal Articles

Bortezomib (Velcade™) Observational Study in China - Efficacy and Safety of Bortezomib Based Regimen in 223 Relapsed or Refractory Multiple Myeloma Patients.

Zhi-xiang Shen, MD

Blood (2007) 110 (11): 4833.

https://doi.org/10.1182/blood.V110.11.4833.4833

Published: 2007

Journal Articles

Rituximab plus CHOP (R-CHOP) overcomes PRDM1 -associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma

Yan-Yan Liu, Christophe Leboeuf, Jing-Yi Shi, Jun-Min Li, Li Wang, Yang Shen, José-Francisco Garcia, Zhi-Xiang Shen, Zhu Chen, Anne Janin, Sai-Juan Chen, Wei-Li Zhao

Blood (2007) 110 (1): 339–344.

https://doi.org/10.1182/blood-2006-09-049189

Published: 2007

NARROW

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

Bortezomib-Based Induction Therapy Followed by High-Dose Chemotherapy and Autologous Stem Cell transplantation in Newly-Diagnosed Myeloma: Initial Report From a Chinese Multiple-Center Study

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Long-Term Outcome of Imatinib Treatment in Chronic Myeloid Leukemia (CML) Patients in Shanghai: An International Patient Assistance Programs (GIPAP) Analysis.

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

A Multicentre, Randomized Study of FLAG Treatment in China(CHORT).

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

A Retrospective Study of Introferon-Alpha Treatment on Chinese Patients with Chronic Myeloid Leukemia

Front-Line Therapy with Arsenic Trioxide/All- Trans -Retinoic Acid Combination and Chemotherapy Improves Cure Rates in Newly Diagnosed Patients with Acute Promyelocytic Leukemia

Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial

Bortezomib (Velcade ™ ) Observational Study in China: Efficacy and Safety of Bortezomib-Based Regimen in 395 Relapsed or Refractory Multiple Myeloma Patients

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor

Bortezomib (Velcade™) Observational Study in China - Efficacy and Safety of Bortezomib Based Regimen in 223 Relapsed or Refractory Multiple Myeloma Patients.

Rituximab plus CHOP (R-CHOP) overcomes PRDM1 -associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only